Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cymabay Therapeutics, Inc. (CBAY)  
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 114,780,000
Market Cap: 3.73(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $7.47 - $32.48
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 51,301
Total Buy Value $0 $0 $0 $100,037
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 6,000 235,302 552,511 672,611
Total Sell Value $191,849 $4,692,766 $8,944,114 $10,085,429
Total People Sold 1 5 6 7
Total Sell Transactions 1 14 33 36
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 165
  Page 3 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Shah Sujal Chief Executive Officer   •       •      –    2023-10-09 4 AS $14.20 $921,286 D/D (64,861) 171,301 124%     
   Shah Sujal Chief Executive Officer   •       •      –    2023-10-09 4 OE $5.00 $324,305 D/D 64,861 236,162     -
   Emster Kurt Von Director   –       •      –    2023-09-29 4 AS $15.68 $249,675 D/D (15,921) 90,000 67%     
   Emster Kurt Von Director   –       •      –    2023-09-29 4 OE $5.00 $79,605 D/D 15,921 105,921     -
   Mcwherter Charles President of R&D   •       –      –    2023-09-18 4 AS $16.22 $352,733 D/D (21,746) 15,000 44%     
   Mcwherter Charles President of R&D   •       –      –    2023-09-18 4 OE $5.00 $108,730 D/D 21,746 36,746     -
   Menold Daniel Vice President, Finance   •       –      –    2023-09-15 4 AS $16.87 $0 D/D (0) 0 36%     
   Menold Daniel Vice President, Finance   •       –      –    2023-09-15 4 OE $1.72 $28,612 D/D 16,545 15,000     -
   Quinlan Paul T General Counsel   •       –      –    2023-09-15 4 AS $16.87 $894,141 D/D (53,000) 0 36%     
   Quinlan Paul T General Counsel   •       –      –    2023-09-15 4 OE $2.94 $155,820 D/D 53,000 24,000     -
   Mcwherter Charles President of R&D   •       –      –    2023-08-18 4 AS $11.47 $249,359 D/D (21,746) 15,000 106%     
   Mcwherter Charles President of R&D   •       –      –    2023-08-18 4 OE $5.00 $108,730 D/D 21,746 36,746     -
   Menold Daniel Vice President, Finance   •       –      –    2023-08-15 4 AS $11.92 $0 D/D (0) 0 73%     
   Menold Daniel Vice President, Finance   •       –      –    2023-08-15 4 OE $1.06 $79,010 D/D 15,500 7,000     -
   Quinlan Paul T General Counsel   •       –      –    2023-08-15 4 AS $11.91 $59,551 D/D (5,000) 0 73%     
   Quinlan Paul T General Counsel   •       –      –    2023-08-15 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Menold Daniel Vice President, Finance   •       –      –    2023-08-09 4 AS $12.35 $258,744 D/D (20,945) 0 74%     
   Menold Daniel Vice President, Finance   •       –      –    2023-08-09 4 OE $5.00 $104,725 D/D 20,945 20,945     -
   Mcwherter Charles President of R&D   •       –      –    2023-07-18 4 AS $11.43 $248,519 D/D (21,749) 15,000 53%     
   Mcwherter Charles President of R&D   •       –      –    2023-07-18 4 OE $5.00 $108,745 D/D 21,749 36,749     -
   Quinlan Paul T General Counsel   •       –      –    2023-07-14 4 AS $11.81 $59,050 D/D (5,000) 0 61%     
   Quinlan Paul T General Counsel   •       –      –    2023-07-14 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Quinlan Paul T General Counsel   •       –      –    2023-06-30 4 AS $10.05 $50,250 D/D (5,000) 0 50%     
   Quinlan Paul T General Counsel   •       –      –    2023-06-30 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Mcwherter Charles President of R&D   •       –      –    2023-06-20 4 AS $8.16 $177,383 D/D (21,749) 15,000 81%     
  165 Records found
  1  2  3  4  5  6  7   
  Page 3 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us